{'fraction_non_alphanumeric': 0.030395136778115502, 'fraction_numerical': 0.00303951367781155, 'mean_word_length': 5.586666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of imipramine, nomifensine and d-amphetamine on type B monoamine oxidase, cyclic AMP phosphodiesterase and dopamine-beta-hydroxylase.

The three dissimilar structural antidepressant drugs, imipramine, nomifensine and d-amphetamine, were compared for their effects on type B monoamine oxidase, cyclic AMP phosphodiesterase and dopamine-beta-hydroxylase. Three antidepressant drugs caused a dose-dependent inhibition on type B monoamine oxidase. Of the three drugs, imipramine had a most potent effect. Unlike d-amphetamine, both imipramine and nomifensine inhibited the cyclic AMP phosphodiesterase activity at concentrations more than 10(-4)M. No effect was observed below this concentration. All drugs seemed to have little or no effects on the partially purified dopamine-beta-hydroxylase activity. The weak inhibitory effects of nomifensine on these three enzymes may not be attributable to its antidepressant properties. Morphine had no effect on the three enzyme activities.